Expanded National Partnership to Accelerate Vision Care Reform

Glaucoma Australia and Glaukos Announce Expanded National Partnership to Accelerate Vision Care Reform

For immediate release - World Glaucoma Week (8-14 March) 

Glaucoma Australia and global ophthalmic pharmaceutical and medical technology leader, Glaukos, today announced an expanded long-term and patient-centered partnership supporting the acceleration and rollout of Australia’s first National Action Plan for Glaucoma.

The strengthened collaboration builds on several years of partnership between the two organisations and reflects growing national momentum toward earlier detection, improved patient support, and empowered patient decision-making in available treatments and management for those living with glaucoma.

The partnership - which is underpinned by funding, intellectual leadership and exposure - will support key initiatives aligned with the developing National Action Plan, including patient education programs, clinician engagement, community awareness initiatives, and the continued expansion of Glaucoma Australia’s patient support services.

The announcement comes as part of World Glaucoma Week 2026, where Glaucoma Australia begins celebrating its 40^th anniversary in servicing and supporting people living with glaucoma.

Glaucoma remains one of Australia’s leading causes of irreversible blindness, with approximately 50% of people living with the disease currently undiagnosed. The developing National Action Plan seeks to shift this trajectory through earlier detection, stronger primary care pathways and enhanced patient empowerment, while easing the cost burden to the public system estimated at $5.5Bn per annum.

Adam Check, CEO of Glaucoma Australia, said the partnership represents a critical step toward transforming glaucoma outcomes nationally.

“This partnership reflects a shared commitment to ensuring Australians at risk of glaucoma are diagnosed earlier, supported better, and connected to the care they need throughout their lifelong journey with this disease. The momentum behind the National Action Plan demonstrates what can be achieved when patient organisations, industry and clinicians work together toward system-level change. Glaukos has been an important contributor to this progress, and we are proud to deepen our collaboration as we move into implementation.”

Glenn Fawcett, A-PAC Vice President of Glaukos, said the partnership reinforces Glaukos’ commitment to advancing patient outcomes through innovation and collaboration.

“At Glaukos, our mission is to transform vision through innovative therapies that meaningfully improve patients’ lives. Our partnership with Glaucoma Australia reflects the power of collaboration in addressing unmet need — supporting patients, advancing awareness, and helping shape a more proactive approach to glaucoma care across Australia. We are proud to support the National Action Plan and the collective effort to prevent avoidable blindness.”

As Glaucoma Australia approaches its 40th anniversary, the expanded partnership signals increasing alignment across the glaucoma ecosystem - spanning patients, clinicians, researchers, government and industry - working together to preserve sight and independence for future generations.

Media Enquiries:

Adam Check, Glaucoma Australia
E: ceo@glaucoma.org.au
W: www.glaucoma.org.au

About Glaucoma Australia

Glaucoma Australia is the national peak body supporting people living with glaucoma and those at risk. Through education, advocacy and patient support programs, the organisation works to reduce preventable vision loss across Australia.

About Glaukos

Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing and commercialising novel therapies designed to transform the treatment of chronic eye diseases.